FDA should judge drugs on what they do in real life, not just in companies' clinical trials
Under the new leadership of Marti Makri, the FDA should pay more attention to the important role Real world clinical data – Such as health insurance database – In the ongoing evaluation of drug safety and efficacy, beyond the original clinical trials presented for FDA approval. Issues with drug safety and efficacy can be remembered…
